Want to join the conversation?
In 2Q16, $STJ posted Atrial Fibrillation product sales of $324MM, up 13% from 2Q15. Heart Failure product sales were $384MM, up 48% and sales of neuromodulation products were $140MM, up 19% from last year. Total cardiovascular sales were $319MM, up 1%. Total CRM sales were $395MM, up 8% from 2Q15.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.